Community post

The Mayo Clinic has invested $1.75 million in Adaptive Phage Therapeutics, which will allow APT to initiate a clinical trial to address periprosthetic joint infections (an estimated commercial market of $900 million per year). The trial is set to start in the fall of 2020, with anticipated commercial availability in 2023.